Differential analysis of tumour compartments has revealed that patients with triple-negative breast cancer responsive to chemotherapy exhibit high STING protein levels (Kulasinghe et al., 2021), indicating its presence in the TME of breast cancer and its potential as a treatment target. This evidence concerns the gene STING1 and neoplasm.